semaglutide injections near moreno valley WeightLossandWellnessMV Weight Loss and Wellness |

If youve been searching for solutions, you might be surprised to learn that GLP-1 agonistsmedications originally designed for diabetes and weight managementcould be a game-changer for perimenopausal symptoms

The results, published Monday in NEJM Evidence, represent the first randomized clinical trial exploring semaglutide use in people with Type 1 diabetes, for whom the drug is not currently FDA approved

But the latest trend in microdosing involves taking small amounts of the popular weight-loss medications known as GLP-1s

According to the SmPCs for these medications, the most frequently reported gastrointestinal adverse effects include nausea, vomiting, diarrhoea, constipation, abdominal pain, abdominal distension, dyspepsia and flatulence

The medicines primary patents are due to expire in Canada, China, India and Brazil in 2026, and in other markets between 2028 and 2032

Song, Lijun